Last reviewed · How we verify
NM-IL-12
At a glance
| Generic name | NM-IL-12 |
|---|---|
| Also known as | rHu-IL12, HemaMax, rHu-IL12 |
| Sponsor | Neumedicines Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Upper Respiratory Tract Infection
- Arthralgia
- Abdominal Pain
- Headache
- Crohn's Disease
- Pyrexia
- Nasopharyngitis
- Nausea
- Vomiting
- Diarrhoea
- Fatigue
- Back Pain
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (PHASE1)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (PHASE1)
- Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (PHASE1)
- Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (PHASE1, PHASE2)
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (PHASE3)
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM-IL-12 CI brief — competitive landscape report
- NM-IL-12 updates RSS · CI watch RSS
- Neumedicines Inc. portfolio CI